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Most transcription factor families contain highly
related paralogs generated by gene duplication,
and functional divergence is generally accomplished
by activation of distinct sets of genes by each mem-
ber. Here we compare the molecular functions of
Myf5 and MyoD, two highly related bHLH transcrip-
tion factors that regulate skeletal muscle specifica-
tion and differentiation. We find that MyoD and
Myf5 bind the same sites genome-wide but have
distinct functions: Myf5 induces histone acetylation
without Pol II recruitment or robust gene activation,
whereas MyoD induces histone acetylation, recruits
Pol II, and robustly activates gene transcription.
Therefore, the initial specification of the muscle line-
age by Myf5 occurs without significant induction of
gene transcription. Transcription of the skeletal mus-
cle program is then achieved by the subsequent
expression of MyoD, which binds to the same sites
asMyf5, indicating that each factor regulates distinct
steps in gene initiation and transcription at a shared
set of binding sites.
INTRODUCTION
Many transcription factors belong to larger families of highly
related paralogs that bind to a similar DNA sequence motif.
Functional divergence among related transcription factors within
a family is commonly achieved through divergence of the factor
DNA binding domain. For example, while many of the ETS family
members bind to a shared set of sequences to activate a shared
transcriptional program, each factor also binds a factor-specific
set of sites that have diverged from the shared sequence motifs
to achieve factor-specific gene activation (Hollenhorst et al.,
2007, 2009). Similarly, different members of the NF-kB family
bind the same consensus motifs, but single nucleotide differ-
ences determine which co-activators will form productive inter-
actions with the bound factors at individual sites, thus achieving
factor-specific gene activation in the context of a largely overlap-Developmping set of binding sites (Leung et al., 2004). In both cases, func-
tional diversity within the family is driven by the divergence of the
DNA binding domain and the bound sequence motif. A similar
model has been proposed for the hormone receptors, where
the binding site sequence induces an allosteric regulation of
the transcriptional activity of glucocorticoid receptors (Meijsing
et al., 2009) and in the non-steroid hormone receptor family
where the spacing between motifs determines which family
members can regulate specific genes (Rastinejad, 2001). Thus,
in these examples, functional divergence within transcription
factor families is achieved by factor-specific binding site diver-
gence to allow the regulation of a factor-specific set of genes.
Alternatively, some families have paralogs that bind to the
same set of sites but have different functions. For example, the
opposite repressor and activator functions of the ETS factors
Yan and pntPI on a common set of genes during Drosophila
development (Gabay et al., 1996), or the E2F family members
sequentially recruited to the same genes to variably activate or
repress transcription (Stevaux and Dyson, 2002; Takahashi
et al., 2000).
The basic-helix-loop-helix (bHLH) transcription factor family
binds to an E-boxmotif (CANNTG) and has110members in hu-
mans (Gray et al., 2015) generated by multiple rounds of gene
duplication and functional divergence (Simionato et al., 2007;
Skinner et al., 2010). For MyoD and NeuroD2, two members of
the bHLH family that regulate myogenesis and neurogenesis,
respectively, functional specificity is determined largely by diver-
gence in binding site preference. While both factors bind to a
shared E-box sequence (CAGCTG), NeuroD2 and MyoD also
bind distinct, or ‘‘private,’’ E-box sequences (CAGATG and
CAGGTG, respectively), and these private binding sites are
more strongly associated with lineage-specific gene transcrip-
tion (Fong et al., 2012). For NeuroD2, the greater transcriptional
activity at the private binding sites correlated with a slower off-
rate compared with the shared site. Swapping bHLH regions
was sufficient to redirect MyoD to NeuroD2 private binding sites
and convert MyoD into a neurogenic transcription factor (Fong
et al., 2015). Therefore, functional divergence between two
sub-families of bHLH factors that specify distinct cell lineages
again appears to be driven by factor-specific binding site diver-
gence, rather than differences in the inherent function of the
factor.ental Cell 36, 375–385, February 22, 2016 ª2016 Elsevier Inc. 375
It is less clear how functional divergence is establishedwithin a
subgroup of factors that have sequential roles in the specifica-
tion and differentiation of a single cell lineage. The specification
and differentiation of skeletal muscle cells is determined by the
sequential expression of four myogenic bHLH proteins: Myf5,
MyoD, Myog, and Mrf4. Initial genetic studies suggested that
Myf5 and MyoD were redundant regarding the specification of
the skeletal muscle lineage (Braun et al., 1992, 1994; Kablar
et al., 1997), however, subsequent studies showed satellite cell
differentiation was impaired inMyoD/mice despite expression
ofMyf5 in these cells (Megeney et al., 1996; Sabourin et al., 1999;
Yablonka-Reuveni et al., 1999). Together with the observations
that some muscles have delayed differentiation during develop-
ment in MyoD/ mice and that Myf5 failed to compensate for
MyoD when knocked into theMyoD locus inMyf5/ mice (Hal-
dar et al., 2014; Kablar et al., 1997), these studies suggest that
MyoD and Myf5 might have some distinct functions in muscle
specification and differentiation. In this regard, some studies
suggested that MyoD and Myf5 each established a separate
muscle lineage and had only partially overlapping binding sites
(Gensch et al., 2008; Haldar et al., 2008; Kablar et al., 1997; Sol-
eimani et al., 2012). These findings are consistent with the
general model of functional divergence established through
factor-specific binding site divergence and gene activation.
However, more recent studies support a single muscle lineage
with the sequential expression of Myf5 and MyoD acting to
specify and initiate skeletal muscle differentiation (Comai et al.,
2014); yet in this model the specific functions for each factor
remain unknown.
In the current study, we compared the binding and factor-
specific activity of Myf5 and MyoD. We found that the myogenic
bHLH family appears to have maintained the same binding site
specificity but instead achieved functional divergence by segre-
gating specific steps in transcriptional activation among factors
sequentially expressed during the specification and differentia-
tion of skeletal muscle cells. Specifically, we show that Myf5,
the first factor to specify the skeletal muscle lineage, modifies
the chromatin at its binding sites but does not robustly recruit
Pol II or activate gene transcription, whereas MyoD binds the
same sites but robustly recruits Pol II and activates gene tran-
scription. Our results indicate that Myf5 and MyoD have
achieved functional divergence at a shared set of binding sites
by segregating specific steps in gene initiation and transcription.
In addition, this identifies an early role in lineage specification for
transcription factors that induce regional histone modification
but do not robustly induce transcriptional activation.
RESULTS
Myf5 Is a Weak Transcriptional Activator
To compare the direct effects of MyoD and Myf5 on the expres-
sion of myogenic target genes, we expressed each factor at
equivalent and physiologically relevant levels in mouse embry-
onic fibroblasts lacking endogenous MyoD and Myf5 (M&M
MEFs). For simplicity, we have designated the amount of lenti-
MyoD required to match endogenous MyoD levels in C2C12
muscle cells as ‘‘1x’’ (Figure S1). 1x lenti-Myf5 is the amount of
lenti-Myf5 virus needed to express the Myf5 protein at the
same level as the endogenous MyoD protein (Figure S2). To do376 Developmental Cell 36, 375–385, February 22, 2016 ª2016 Elsevthis, we compared MyoD and Myf5 protein levels from trans-
duced M&M MEFs to Flag-tagged standards using quantitative
western blots (Figure S2). This approach normalized for differ-
ences in antibody affinity, allowing a direct relationship between
MyoD and Myf5 protein levels to be inferred (see Experimental
Procedures and Figure S2 for additional details). We also
ensured that we were not underexpressing Myf5 relative to
endogenous levels by comparing Myf5-transduced M&M
MEFs to cycling and differentiating C2C12s (Figure S1).
To compare the relative ability of MyoD orMyf5 to inducemus-
cle cell differentiation, we transduced M&M MEFs with 1x of
either lenti-MyoD or lenti-Myf5, and then switched them to differ-
entiation media (DM). After 3 days in DM, we observed a large
number of differentiating myocytes and myotubes in the cells
transduced with lenti-MyoD (Figure 1A, top panel) but none in
control cells transduced with lenti-GFP (Figure 1A, bottom
panel). Although we observed a few elongated myocytes in the
Myf5-transduced cells, no multinucleated myotubes were
visible, and the cells generally resembled the GFP-transduced
M&M MEFS (Figure 1A, middle panel). Overexpressing Myf5
4-fold or more induced some increase in muscle cell formation,
but still not as robustly as lower levels of MyoD (Figure S3).
To assay gene expression changes induced by MyoD and
Myf5, we performed RT-qPCR on M&M MEFS transduced with
1x lenti-MyoD or lenti-Myf5. After transduction for 18 hr, the cells
were recovered in growth media for 6 hr and then switched into
DM. To focus the assay on direct effects of MyoD and Myf5, we
assayed gene expression changes after only 20 hr in DM, a time
when Myog mRNA becomes detectable but myogenin protein
levels are still very low (data not shown). We observed dramatic
increases in the expression of Myog and Chd15 in response to
MyoD (Figure 1B). In contrast, these genes were only weakly
induced by Myf5 under the same conditions (Figure 1B).
We next considered that Myf5 levels might be just under some
threshold necessary for induction. Increasing the amount of
Myf5 in M&M MEFs up to 4-fold did result in increased expres-
sion of target genes, however, 4x Myf5 resulted in only approx-
imately 30%–40% of Myog and Cdh15 mRNA compared with
cells expressing 1x MyoD (Figure 1B). We validated that
increasing the amount of lenti-Myf5 did indeed increase the
amount of Myf5 protein expressed in the cells by quantitative
western blot (Figure S2B). These data, combined with the poor
differentiation of M&M MEFs transduced with Myf5, suggested
that either Myf5 was a relatively poor transcription factor,
requiring substantial overexpression for differentiation, or that
Myf5 induced a distinct set of myogenic genes not assayed in
our RT-qPCR experiments.
To determine whether Myf5 more strongly induced a distinct
set of genes, or a subset of the MyoD regulated genes, we per-
formed RNA-seq on M&M MEFs transduced with 1x lenti-MyoD
or 1x lenti-Myf5. To control for changes in gene expression due
to viral transduction, we transduced M&M MEFs with a range of
lenti-GFP, and all genes that displayed a dose-response to lenti-
GFP transduction were excluded from the analysis (Figures
S3D–S3G). When we examined the scatterplots of the RNA-
seq data, we found that both MyoD and Myf5 upregulated a
similar set of genes, however, Myf5 upregulated these genes
very weakly (Figures 1C–1E). Thus we conclude that Myf5
does not induce a distinct subset of genes compared withier Inc.
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Figure 1. Myf5HasWeak Transcriptional Ac-
tivity Compared with MyoD
(A) Phase contrast images of M&M MEFs trans-
duced with either 1x lenti-MyoD or 1x lenti-Myf5 for
1 day and then switched to DM for 3 days.
(B) M&M MEFs were transduced with a range of
lenti-MyoD or lenti-Myf5 titers for 24 hr then
switched to DM for 20 hr. Expression of Myog and
Cdh15 was assayed by RT-qPCR, using mRpl17a
as an internal control.
(C) RNA-Seq data from M&M MEFs transduced
with either 1x lenti-MyoD or 1x lenti-Myf5 for 24 hr
then switched to DM for 20 hr. Data points depict
the log2 fold change over non-transduced cells.
Genes showing a dose-response to increasing
amounts of lenti-GFP were removed from the
analysis to eliminate confounding viral-response
effects. The red line represents the fitted trend line
comparing MyoD and Myf5 while the black line
represents a slope of 1.
(D) RNA-seq reads over the myogenin locus. All
tracks have the same scale.
(E) Genes upregulated at least 4-fold byMyoDMyf5
with p values less than 1010. Genes identified as
‘‘viral response’’ (Figure S3) have been removed
from the analysis. See also Figures S1–S3.MyoD, but rather weakly induces expression of the same genes
more robustly activated by MyoD.
MyoD and Myf5 Bind the Same Genomic Locations
MyoD andMyf5 both bind DNAmotifs containing the core E-box
consensus sequence CANNTG. To determine whether MyoD
and Myf5 bound the same set of E-boxes genome-wide, we
used chromatin immunoprecipitation coupled with high-
throughput sequencing (ChIP-seq), using the same lentiviral
expression system in M&M MEFs as in the RNA-seq study
above. We found that, in DM conditions, MyoD and Myf5 peaks
looked quite similar (Figure 2A) and were highly correlated
genome-wide (R2 of 0.86) (Figure 2B).
A direct comparison of peaks from the MyoD and Myf5 ChIP-
seq datasets is inherently challenging due to the differential af-
finities of each antibody, and any threshold chosen is likely to
include peaks in one dataset that narrowly miss the cut-off in
the other. To avoid the problem of thresholding when deter-
mining peak overlap, we used a rank-based approach to
compare the peak lists. For this analysis, we ranked peaks ac-
cording to their p values, then grouped the peaks into bins
based on their rank and plotted the degree of overlap withinDevelopmental Cell 36, 375–385,the corresponding bins as a heatmap
(Figure 2C). Overall there is a near perfect
concordance of binding sites between
MyoD and Myf5. Motif analysis of the re-
gions bound by MyoD or Myf5 also iden-
tified the same E-box motifs (Figures 2D
and 2E). Thus, we conclude that while
Myf5 only weakly induces myogenic tar-
gets, it binds to the same sites as
MyoD, suggesting the low gene induction
is not due to a difference in the E-boxsequence preference and/or a difference in the genomic sites
bound.
Myf5 Induces Regional Histone H4 Acetylation around
Its Binding Sites
In addition to activating target genes, MyoD induces chromatin
remodeling and histone acetylation at its binding sites (Cao
et al., 2006, 2010; de la Serna et al., 2001; Gerber et al., 1997).
To determine whether Myf5 induced chromatin modifications,
we transduced M&M MEFs with 1x lenti-MyoD or lenti-Myf5,
and then assayed global patterns of H4 acetylation (H4Ac) by
ChIP-seq using a pan-H4Ac antibody. Active genes that are
not targets of either MyoD or Myf5, such as Fn1, have strong
peaks of H4Ac in all samples providing a positive control for
each ChIP dataset (Figure 3A). In accordance with previous
studies of MyoD (Cao et al., 2010), we found widespread in-
creases in H4Ac adjacent to MyoD binding sites in MyoD-
transduced M&M MEFS (Figures 3B and 3C). Transduction
with lenti-Myf5 also increased H4Ac around Myf5 bound sites
to the same degree as MyoD (Figures 3B–3D), whether we
used the sites that met the cut-off criteria as bound by MyoD
or bound by Myf5 (Figures 3C and 3D).February 22, 2016 ª2016 Elsevier Inc. 377
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Figure 2. MyoD and Myf5 Bind the Same
Subset of E-Boxes
(A) ChIP-seq reads over the Cdh15 promoter. The
mock ChIP samples are from cells transduced with
lenti-GFP and immunoprecipitated with antibodies
against Myf5 orMyoD. The tracks scales have been
normalized using the average peak height to ac-
count for differences in the two antibody effi-
ciencies.
(B) Overlap of MyoD and Myf5 ChIP-seq peaks
plotted by peak coverage.
(C) Rank comparison of the top 50,000 MyoD and
Myf5 peaks. Each box in the plot represents the
overlap of two ranked peak lists. The bins are or-
dered from the origin as follows: top 5,000 peaks,
top 10,000 peaks, etc. The color scale indicates the
fraction of loci in the bin bound by both MyoD and
Myf5.
(D) Motifs enriched under MyoD or Myf5 peaks.
(E) The ratio of the number of peaks containing the
motif compared with the number of control regions
containing the motif.As a control for the specificity of the H4Ac changes, we exam-
ined H4Ac changes around the set of E-boxes not bound by
MyoD or Myf5 in M&M MEFs. We chose E-boxes that are
capable of being bound by MyoD in P19 cells, but are not bound
byMyoD inM&MMEFs due to occlusion of these E-boxes by nu-
cleosomes (Fong et al., 2012). We find these E-boxes have small
peaks of H4Ac in all three samples directly over the E-boxes,
indicating that these E-boxes are indeed occluded by nucleo-
somes in M&M MEFs and are neither bound by, nor have
increased H4Ac in response to MyoD or Myf5 (Figure 3E). Taken
together, these data indicate that Myf5 and MyoD induce similar
levels of local H4Ac at the same genomic sites, despite the rela-
tively poor transcriptional activity of Myf5.
Myf5 Stably BindsE-Boxes but Lacks aStrongActivation
Domain
Our previous studies on the neurogenic bHLH transcription fac-
tor NeuroD2 identified binding affinity to different E-box se-
quences as a determinant of whether NeuroD2 would induce
both transcription and H4Ac, or only induce H4Ac (Fong et al.,378 Developmental Cell 36, 375–385, February 22, 2016 ª2016 Elsevier Inc.2012, 2015). Although MyoD and Myf5
bind the same sites, it is possible that
Myf5 binding is less stable, allowing
H4Ac but not transcription. To compare
the relative stability of MyoD and Myf5,
we used in vitro gel shift assays with
probes containing either single or paired
E-boxes, similar to the assay used to
compare NeuroD2’s relative stability on
different sequences (Fong et al., 2015).
To determine the off-rates, cold compet-
itor was added to the binding reaction at
time = 0 and samples were incubated for
a range of times and then loaded onto a
running gel (see Experimental Proce-
dures). The decreasing intensity of the
shifted probe allows the off-rates betweenthe protein complexes and DNA to be compared. The off-rates
from either a single E-box (Figures 4A and 4C) or a paired
E-box (Figures 4B and 4D) were similar between MyoD and
Myf5. In addition, we tested the binding kinetics of a chimeric
protein created by fusing the N-terminal activation domain of
MyoD to the N terminus of Myf5 (described below). We found
the off-rates for this chimera were nearly identical to MyoD and
very similar to Myf5 for both single and paired E-boxes. Based
on these in vitro binding assays, we conclude that binding affin-
ity, as indirectly measured by the off-rate, is unlikely to account
for the transcriptional difference between MyoD and Myf5.
The low induction of myogenic genes coupled with the
genome-wide binding data led us to ask whether Myf5 lacks a
strong activation domain. We directly compared the activation
strength of the non-bHLH domains of MyoD and Myf5 in vivo
by fusing portions of each protein to the Gal4 DNA binding
domain (Figure 5A). These fusions were co-transfected into
C2C12 myoblasts together with a plasmid containing a lucif-
erase gene with four Gal4 binding sites near its promoter. As ex-
pected, the previously characterized N-terminal activation
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Figure 3. MyoD and Myf5 Induce Compara-
ble Levels of Local Histone H4 Acetylation
(A and B) H4Ac ChIP-seq reads at the Fibronectin-1
promoter (positive control locus) (A), and an inter-
genic region of Chr12 surrounding a common
MyoD/Myf5 peak (B). M&M MEFs were transduced
for 24 hr and then switched into DM for an addi-
tional 20 hr.
(C–E) Average H4Ac around MyoD (C), Myf5 (D), or
control (E) peak lists from M&M MEFs transduced
with lenti-GFP, lenti-MyoD, or lenti-Myf5. ‘‘0’’ de-
notes the center of the MyoD or Myf5 meta-peaks
and the plots extend 500 bp to either side. Control
E-boxes are E-boxes bound by MyoD in P19 cells
but not in MEFs. The graphic below represents
theoretical locations of positioned (solid lines) and
non-positioned nucleosomes (dotted lines) sur-
rounding E-box binding sites.domain ofMyoD induced robust reporter gene expression (Wein-
traub et al., 1991), whereas neither the N-terminal nor C-terminal
domain of Myf5 had comparable reporter gene activation (Fig-
ure 5B). The MyoD N-terminal activation domain was approxi-
mately 11-foldmore potent at reporter gene induction than either
of the potential activation domains of Myf5. We repeated this
experiment in fibroblasts to rule out any muscle-specific MyoD
or Myf5 cofactors, with the same result (Figure S4A). Because
Myf5 has previously been shown to have two domains that
exhibit enhanced transcriptional activity when combined (Braun
et al., 1990; Winter et al., 1992), we also replaced the bHLH do-
mains of MyoD and Myf5 with the Gal4 DBD, leaving both the N-
and C-terminal regions of MyoD and Myf5 intact in the same
fusion protein. Indeed, this showed a slight improvement in the
transcriptional activity of the Myf5 fusion protein, but the MyoD
fusion protein demonstrated more than a 5-fold higher transcrip-
tional activity (Figure 5B). These results suggested that the rela-
tively weak induction of muscle genes byMyf5 in vivo was due to
the absence of a strong activation domain, and that it might be
possible to ‘‘rescue’’ the transcriptional activity of Myf5 by add-
ing a stronger activation domain.
To test ‘‘rescue’’ of Myf5-induced transcription, we fused the
N-terminal activation domain of MyoD to the N terminus of
Myf5 (Myf5-Chimera) (Figure 5A). In vitro binding assays showed
that the Myf5-Chimera bound to MyoD/Myf5 E-boxes with ki-
netics similar to MyoD and Myf5 (see Figure 4). Lentiviral trans-Developmental Cell 36, 375–385duction of M&M MEFs with Myf5, MyoD,
and the Myf5-Chimera at equivalent levels
showed that the chimera activated endog-
enous gene expression equivalently to
MyoD, based on RT-qPCR of the target
genes Myog and Cdh15 (Figure S4B). A
comparison of RNA-seq profiles from cells
transduced with either MyoD or the
Myf5-Chimera demonstrated equivalent
genome-wide transcriptional activation
after 20 hr in DM (Figures 5C and 5D).
Furthermore, equivalent gene induction
and morphological changes were ob-
served after 48–72 hr in DM (FiguresS4C–S4E), demonstrating that the relatively inefficient transcrip-
tional activation by Myf5 can be complemented by the addition
of the MyoD acidic activation domain. Conversely, a chimera
that replaced the Myf5 bHLH domain with the bHLH domain of
MyoD (Myf5-MDbHLH) lacked the ability to robustly induce
gene expression, but was capable of inducing histone H4 acet-
ylation (Figures S4F–S4G). It is interesting to note that a MyoD
mutant lacking its N-terminal acidic activation domain main-
tained the ability to induce H4 acetylation (Figure S4G), indi-
cating that, for both Myf5 and MyoD, the regions necessary for
HAT recruitment function independently from transcriptional
activation. Together these results indicate that Myf5 has weaker
transcriptional activation domains when compared with MyoD.
Myf5 Does Not Efficiently Recruit Pol II to Myogenic
Promoters
Most transactivation domains both recruit Pol II and promote Pol
II release. To determine whether the relatively poor transcrip-
tional activity of Myf5 was due to poor recruitment and
elongation of Pol II, we examined levels of total Pol II (N-20), un-
phosphorylated Pol II (8WG16), and elongating Pol II (phosphor-
ylated on Ser2) at myogenic loci following transduction with
lenti-GFP, -MyoD, or -Myf5. Inspection of the 50 and 30 ends of
Myog andChrng by qPCR of the chromatin immunoprecipitation
(ChIP) material demonstrated a robust recruitment of total and
unphosphorylated Pol II at the 50 ends, and elongating Pol II at, February 22, 2016 ª2016 Elsevier Inc. 379
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Figure 4. MyoD and Myf5 Have Similar Bind-
ing Kinetics
(A and B) EMSA: in vitro translated MyoD, Myf5, or
Chimera was mixed with E12 and hot probes con-
taining a single GG E-box (A), or a pair of GG
E-boxes (B). The cold competitor is the same
sequence as the hot probe.
(C and D) EMSA band intensity is plotted as a
function of the time incubated with the cold
competitor.the 30 ends in MyoD expressing cells. However, occupancy of all
three forms of Pol II was substantially lower followingMyf5 trans-
duction (Figures 6A and 6B). This suggested that Myf5 did not
efficiently recruit Pol II, as opposed to recruiting Pol II that would
remain paused at the promoter. To test if low Pol II recruitment
was indeed dependent on the activation domain we repeated
the ChIPs for Pol II (using the 8WG16 Ab) and included the
Myf5-Chimera in the assay. In accordance with our previous
findings, Pol II recruitment to the 50 end of geneswas significantly
lower in cells expressing Myf5 (Figures 6C and 6D). In contrast,
the chimera recruited Pol II as well as or better than MyoD (Fig-
ures 6C and 6D). To ensure our ChIPswere working in each sam-
ple, we also assayed a region of ch7 devoid of transcription
(negative control) (Figure 6E) and the 50 region of the highly ex-
pressed Fn1 gene (positive control) (Figure 6F). This suggests
that the primary reason for poor expression of target genes by
Myf5 is inefficient recruitment of Pol II by a strong activation
domain. Interestingly, however, co-expression of Myf5 and
MyoD in M&M MEFs resulted in target gene expression levels
that were greater than the sum achieved by either factor ex-
pressed alone, indicating Myf5 is not acting as a repressor or380 Developmental Cell 36, 375–385, February 22, 2016 ª2016 Elsevier Inc.competitive antagonist, but rather might
have a positive function in gene regulation
that enhances the activity of MyoD
(Figure S5).
DISCUSSION
This study demonstrates that the major
difference between Myf5 and MyoD is
a divergence of transcriptional activity
rather than a divergence of binding site/
sequence preference. Using balanced
MyoD and Myf5 levels, we found the bind-
ing profiles of MyoD and Myf5 were iden-
tical genome-wide; yet robust induction
of transcription from myogenic genes
was not seen in cells expressing Myf5, a
deficiency that was due to a lack of Pol II
recruitment by Myf5 rather than a differ-
ence in binding stability. However, we
found Myf5 is capable of altering chro-
matin structure by inducing the acetyla-
tion of histone H4 around its binding sites.
This chromatin remodeling function,
together with the evolutionary conserva-
tion of Myf5, are consistent with a hierar-chical model where the early specification factor works largely
through chromatin-based mechanisms, and later factors bind
to the same sites and drive differentiation through transcriptional
activation of the previously chromatin remodeled genes.
Different Efficiencies of Myf5-Driven Muscle
Differentiation during Development
Consistent with our findings, the differentiation of muscle satel-
lite cells in adult MyoD-null mice is impaired despite increased
expression of Myf5, indicating that Myf5 does not efficiently sub-
stitute for MyoD in these cells (Megeney et al., 1996; Sabourin
et al., 1999; Yablonka-Reuveni et al., 1999). During embryonic
development of MyoD-null mice, differentiation of skeletal mus-
cle occurs in the absence of MyoD (although it is delayed in
severalmuscle groups), and it is thought that the increased levels
ofMyf5 are sufficient to overcome the lack of MyoD (Kablar et al.,
1997; Rudnicki et al., 1992). This phenotype is also consistent
with our observation that 4-fold higher levels of Myf5 will partially
activate Myog expression and induce MEF differentiation (see
Figures S3A–S3C). It is interesting to note, however, that some
skeletal muscle forms in the embryo prior to MyoD expression.
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Figure 5. Addition of a Strong Acidic Activa-
tion Domain to the N Terminus Imbues Myf5
with Robust Gene Activation Potential
(A) Schematics depicting MyoD andMyf5 domains,
the Myf5-Chimera, and the Gal4 fusion constructs.
AD, activation domain; H/C, HisCys region
(required for interaction with Pbx); H3, helix 3.
(B) Myod- or Myf5-Gal4 fusion constructs were co-
expressed in differentiating C2C12s with a Gal4-
Luc reporter. The data represent the average of
three biological replicates and the error bars
represent the SD from the mean.
(C and D) RNA-Seq data from M&M MEFs trans-
duced with either lenti-MyoD or lenti-Chimera for
24 hr and then switched to DM for an additional
20 hr. Genes showing a dose-response to
increasing amounts of lenti-GFP were removed
from the analysis. The black line indicates a linear
trend line fitted to the data. Genes that were
induced 2-fold or more (log fold change of 1) by
MyoD (C) or all genes (D) are displayed. See also
Figure S4.This muscle formation is delayed inMyf5-null mice (Braun et al.,
1992; Ott et al., 1991; Sassoon et al., 1989) and Mrf4-null mice
(Patapoutian et al., 1995), and it is likely that this early muscle for-
mation is driven byMyf5 andMrf4 rather than byMyoD andMyog
(Bober et al., 1991; Cusella-De Angelis et al., 1992; Summerbell
et al., 2002). In fact, some early myogenesis occurs in Myf5-null
mice that is driven by early expression ofMrf4 (Kassar-Duchos-
soy et al., 2004), suggesting that Mrf4 might substitute for the
role ofMyoD in someof the early somiticmuscle cells. In addition,
the different relative dependencies of muscle cells on MyoD for
terminal differentiation, such as the ability of elevated levels of
Myf5 to drive primary skeletal muscle differentiation in MyoD-
null mice but not satellite cell differentiation duringmuscle regen-
eration in these mice, suggest that other factors might also influ-
ence the transcriptional potency of Myf5, whether through global
effects on the efficiency of transcription genome-wide, such as
concentrations of mediator factors, or cofactors that specifically
interact with Myf5 and other bHLH transcription factors. Future
studies focusing on these developmental differences, possibly
aided bymice engineered with chimeric myogenic bHLH factors,
might be able to determine the basis for the apparently differentDevelopmental Cell 36, 375–385,efficiencies of bHLH-driven muscle differ-
entiation in different cells at different
developmental stages.
Myf5 Binds the SameSites Bound by
MyoD
Although MyoD/Myog/Mrf4-null mice
have reduced body mass, many muscle
forming regions, such as the tongue,
have comparable numbers of cells as
wild-type animals, indicating myoblasts
were specified and proliferated but could
not differentiate into myofibers (Valdez
et al., 2000). Because Myf5 is the first
gene to be activated, and because myo-blasts were specified in mice with only Myf5, it was suggested
that each of the related myogenic bHLH proteins had evolved
both specific and redundant functions and that each factorwould
bind a unique set of E-boxes as well as a set common to more
than one family member (Valdez et al., 2000).
A previous study using TAP-tagged MyoD and Myf5 sug-
gested there was limited overlap between the binding of these
two proteins (30%), which could have explained the evolu-
tionary selection to retain both genes (Soleimani et al., 2012).
However, we discovered that a C-terminal TAP-tag, like the
one used by Soleimani et al., disrupted Myf5 function and
blocked normal differentiation when expressed in C2C12 myo-
blasts (M.L.C., unpublished data). When we investigated the
binding patterns of MyoD and Myf5 using untagged versions of
the proteins and physiologically relevant expression levels, we
found no difference between MyoD and Myf5, indicating a
distinct function rather than a difference in binding site prefer-
ence. Our ChIP-seq studies were performed in M&M MEFs,
i.e., MEFs with knockouts of both MyoD and Myf5, to prevent
the complication of cross- and auto-activation. Previously we
showed that MyoD binds the same sites in these MEFs as inFebruary 22, 2016 ª2016 Elsevier Inc. 381
%
 in
pu
t
%
 in
pu
t
Pol II ChIP: 5' region of Myogenin
Pol II ChIP: Chr 7 gene desert
(negative control)
Pol II ChIP: 5' region of Cdh15
A B
%
 in
pu
t
%
 in
pu
t
C D
Chimera Chimera
ChimeraChimera
Fo
ld
 c
ha
ng
e 
ov
er
 th
e 
C
h7
 n
eg
 c
on
tro
l 
E F
Chr 7 Myog (5') Myog (3')
Fo
ld
 c
ha
ng
e 
ov
er
 th
e 
C
h7
 n
eg
 c
on
tro
l 
Chr 7 Chrng (5') Chrng (3')
Pol II ChIP: 5' region of Fn1
(Positive control)
Figure 6. Pol II Recruitment to Myogenic
Loci by MyoD, Myf5, and the Chimera
(A and B) Total Pol II (N-20), unphosphorylated Pol II
(8WG16), and elongating Pol II (Ser2P) occupancy
at the 50 and 30 ends of the Myog gene (A), and the
Chrng gene (B). A single biological replicate was
done for each ChIP and data are represented as the
fold change over the Ch7 negative control region to
minimize technical differences between the three
antibodies.
(C–F) Triplicate ChIPs from each sample using the
8WG16 antibody. Error bars represent the SD of the
three ChIPs. A region of chromosome 7 with no
annotated genes or transcribed retroelements was
used as a negative control (E), and the 50 end of the
Fn1 gene was used as a positive control (F). See
also Figure S5.C2C12 cells and primary muscle cells (Cao et al., 2010), indi-
cating that these are an appropriate cell type for the comparison
of MyoD and Myf5 binding.
MyoD and Myf5 Have Distinct Roles in Specifying the
Muscle Lineage
In mice, Myf5 protein levels become detectable at embryonic
day E8 during early muscle commitment, prior to differentiation,
while MyoD protein levels are not apparent until day E10 during
skeletal muscle differentiation. Both MyoD-null and Myf5-null
mice are capable of generating skeletal muscle, indicating a level
of redundancy between Myf5 and MyoD. Early experiments us-
ing lineage tracing approaches in mice suggested a population
of MyoD-positive myogenic cells that had never expressed
Myf5 (Gensch et al., 2008; Haldar et al., 2008). This led the au-
thors to conclude that perhaps skeletal muscle was really two
distinct lineages, one that required Myf5 and one that required
MyoD. More recent experiments from Comai et al. (2014)
demonstrated that theMyf5 locus does not drive lineage tracing
markers with perfect penetrance, leading to cells that express
Myf5 but are not marked. In their experiments using the long-
lived LacZ as a lineage marker, they found all skeletal muscle
cells expressed Myf5 and concluded that skeletal muscle is
one lineage and that Myf5 is expressed in all muscle progenitor
cells (Comai et al., 2014). Consistent with this conclusion, we
found that Myf5 and MyoD have distinct molecular functions at
a shared set of binding sites. Given their temporal expression
patterns during development, our data suggest that Myf5 and
MyoD act sequentially within the same muscle lineage. Our382 Developmental Cell 36, 375–385, February 22, 2016 ª2016 Elsevier Inc.data demonstrating that Myf5 is a weak
transcription factor that binds the same
sites as MyoD might also explain the lack
of muscle in Myf5-knockout mice with
Myf5 knocked into theMyoD locus (Haldar
et al., 2014).
Lack of Pol II Recruitment Rather
Than Unstable Binding
Distinguishes Myf5 from MyoD
We considered that the lack of Pol II
recruitment and transcriptional activitydisplayed by Myf5 could be due to unstable binding, and that
the formaldehyde crosslinking used in our ChIPs was perhaps
trapping relatively transient Myf5 binding events. We compared
MyoD and Myf5 binding in vitro by comparing their dissociation
rates from target DNA sequences. Because the addition of the
N terminus of MyoD to Myf5 rescued the transcriptional defect
of Myf5, if the transcriptional defect of Myf5 was due to
decreased residency time, we would expect the chimera to
have a slower off-rate than Myf5 and to have dissociation ki-
netics similar to MyoD. However, we discovered very little dif-
ference between the off-rates of the three on single or paired
E-boxes, indicating no inherent difference in binding kinetics
or cooperative stability.
Although we saw no difference in the DNA binding stability be-
tween MyoD and Myf5, the electrophoretic mobility shift assay
(EMSA) experiments were an in vitro measurement of DNA bind-
ing. To determine whether a lack of binding stability in vivo might
account for the poor activation potential of Myf5, we substituted
a Gal4 binding domain for the native bHLH domain and assayed
expression of a Gal4 reporter in vivo. Replacing the bHLH bind-
ing domain with the Gal4 DNA binding domain demonstrated
that the intrinsic activation potential of the MyoD activation
domain was much greater than any of the Myf5 activation do-
mains (singly or in combination), again indicating that the defect
in transcriptional activation is not due to reduced binding stabil-
ity. In addition, replacement of the Myf5 bHLH domain with the
MyoD bHLH domain demonstrated that the weaker transcrip-
tional activity of Myf5 was not secondary to weaker DNA
binding.
Myf5 Induces Chromatin Modification
Histone H4 acetylation is considered a general marker of
‘‘open’’ chromatin and is enriched in both enhancers and pro-
moters (Heintzman et al., 2007). Previously, MyoD binding
was demonstrated to induce H4Ac when expressed in fibro-
blasts (Cao et al., 2010), presumably via interactions with
PCAF and P300 (Puri et al., 1997). If Myf5 functions to specify
muscle progenitors, then it is likely that Myf5 has a largely chro-
matin-based function. Indeed, we find that Myf5 induces local
H4Ac, despite its lack of transcriptional induction. This indi-
cates that Myf5 might functionally precede MyoD during line-
age specification by reorganizing chromatin prior to robust
transcription of differentiation specific genes. Together with
our prior studies showing that Myog binds to the same sites
as MyoD but lacks the ability to access genes in native chro-
matin and initiate chromatin modifications (Bergstrom and
Tapscott, 2001; Cao et al., 2006), these studies demonstrate
that each of these three bHLH factors has a specific molecular
function in the initiation, activation, and maintenance of muscle
gene transcription.Lineage Specification through Chromatin Modification
Our data support a stepwise model where Myf5 has greater ac-
tivity as a chromatin modifier than a transcriptional activator,
MyoD has both functions, and Myog is predominantly a tran-
scriptional activator. In this model, the chromatin-modifying ac-
tivity of Myf5 might facilitate future muscle gene activation by
MyoD and Myog, however, it is also interesting to speculate
that this activity might also prevent the activation of alternative
fates by preventing the expression of those programs. Given
that myoblasts originate in the dermomyotome alongside other
lineages, such as chondroblasts, Myf5 may be important for pre-
venting non-myogenic fates in the cells that express it. Indeed, in
Myf5 null mice, LacZ staining indicates that cells destined to
become muscle undergo the correct epithelial-to-mesenchymal
transition in the developing somite, but can migrate aberrantly
and adopt alternative fates. These cells express the cartilage
marker scleraxis, and the multi-tissue (but non-myogenic) gene
Twist2 (aka Dermo-1), indicating incorrect specification of por-
tions of the dermomyotome (Tajbakhsh et al., 1996). Taken
together, these data suggest Myf5 might not only set up a
genome-wide chromatin structure that is permissive for myo-
genesis but is also refractory to chondrogenesis. One clear
conclusion, however, is that the initial specification of the skel-
etal muscle lineage by Myf5 is not accomplished by robust tran-
scription of the gene networks associated with skeletal muscle
differentiation and likely acts via lineage-specific chromatin
modifications.EXPERIMENTAL PROCEDURES
qPCR Primers and EMSA Oligos
See Supplemental Experimental Procedures.
Antibodies
See Supplemental Experimental Procedures.
Plasmids
See Supplemental Experimental Procedures.DevelopmCell Culture
M&MMEFs were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin
(Gibco). Murine C2C12 myoblasts were collected and cultured as has been
previously described in DMEM + FBS (Cao et al., 2006). Low-serum DM
consisted of DMEM with 1% horse serum, 1% penicillin-streptomycin, and
10 mg/ml each insulin and transferrin.
Determination of Endogenous MyoD and Myf5 Levels
MyoD and Myf5 protein and RNA were isolated from M&M MEFs transduced
with a range of lenti-MyoD or lenti-Myf5 infection titers and comparedwith pro-
tein and RNA isolated from differentiating C2C12 myoblasts. See Supple-
mental Experimental Procedures for additional information.
Balancing MyoD and Myf5 Protein Levels
To determine that MyoD andMyf5 were expressed at equivalent protein levels,
we devised a way to compare them with Flag-tagged standards using quanti-
tative western blots. See Figure S2 and Supplemental Experimental Proce-
dures for additional information.
Immunofluorescence
Cells were fixed for 7 min in 2% paraformaldehyde. Fixation was quenched
with glycine (final concentration of 10 mM). Cells were permeabilized with
PBS containing 0.5% Triton X-100 for 10 min and then blocked with 2%
BSA for 1 hr. Cells were probed overnight at 4C with the anti-MHC antibody
MF-20.
RNA-Seq
RNA-seq and gene expression profiles were compared using the Bio-
conductor package edgeR as done previously by Fong et al. (2012). See Sup-
plemental Experimental Procedures for additional information.
xChIP-Seq for MyoD and Myf5
Cross-linked ChIP was performed as previously described (Cao et al., 2010).
See Supplemental Experimental Procedures for additional information.
mxChIP-Seq for Pol II
Cross-linkedChIP coupledwithMNase digestion was performed as described
in Skene and Henikoff (2015) with two modifications: decreased MNase con-
centration (15 U of Worthington MNase incubated at 37C for 15 min) and
greater sonication intensity (4 pulses at 30% amplitude, 15 s per pulse with
1-min rest between pulses). Pol II antibodies were pre-bound to Protein G
Dynabeads according to the manufacturer’s directions. Beads were washed
and DNA was isolated according to the Skene and Henikoff protocol.
nChIP-Seq for H4AC
Native ChIP for histone acetylation was performed by combining the nuclei
isolation protocol from Gerber et al. (1997) and the MNase digestion and chro-
matin extraction method from Cao et al. (2010). See Supplemental Experi-
mental Procedures for additional information.
ChIP Peak Calling
We used a peak calling and comparison approach previously used by Fong
et al. (2012). See Supplemental Experimental Procedures for additional
information.
ChIP-Seq Sample Comparison
Because it is unclear how to set up a fair comparison baseline due to the dif-
ferences in the antibodies, total number of reads, and foreground/background
read distribution, we adopted a rank-based paradigm to compare ChIP-seq
samples of different transcription factors while still taking the peak p value sig-
nificance into account, as previously described in Fong et al. (2012). We
ranked all peaks by their p values and grouped them by their ranks into bins
of 5,000 (i.e., the top 5K peaks, then the top 10K peaks, etc). Then we
computed the fraction of top x peaks in one sample that overlap with the
top y peaks in another sample, where x and y vary from 5K to 50K, and y is
equal to or greater than x.ental Cell 36, 375–385, February 22, 2016 ª2016 Elsevier Inc. 383
Motif Enrichment Analysis
We used a discriminative de novo motif discovery tool described previously
(Cao et al., 2010; Palii et al., 2011) to find motifs that distinguish foreground
and background sequence datasets. See Supplemental Experimental Proce-
dures for additional information.
Luciferase Assays Using Gal4 Reporters
MyoD and Myf5 domains fused to the GAL4 DNA binding domain were as-
sayed for activation of a Gal4-dependent luciferase reporter. C2C12s were
transfectedwith effector plasmids (Gal4 DNA binding domain fused to portions
of MyoD or Myf5) and the pGal4 reporter plasmid. Cells were grown for 24 hr
after transfection and then assayed as above using the Promega Dual-Lucif-
erase Reporter system. For these luciferase assays, we normalized the Luc/
Ren values for each sample to the average Luc/Ren signal for MyoD-NTerm-
Gal4 effector plasmid samples.
Gel Shifts
Proteins were translated in rabbit reticulocyte lysate using the Promega TNT
quick-coupled translation kit according to the manufacturer’s directions.
32P-labeled oligos were incubated with their reverse complements and then
allowed to slow cool overnight to form duplex DNA probes. For each gel shift
reaction, 1.75 ml of each in vitro translated protein was combined in a 30-ml re-
action containing: 20 mM HEPES [pH 7.6], 50 mM KCl, 1.5 mMMgCl2, 10 mM
DTT, and 1 mM EDTA, and then incubated at 37C for 20 min to allow com-
plexes to form. 1 ng of hot probe was added to each reaction and they were
incubated at room temperature for 15 min to reach equilibrium binding. Cold
competitor was added at various times such that all reactions were assayed
at the same time. At time = 0, all samples were placed on ice and then loaded
onto a running gel (200 V) as quickly as possible. Samples were run on non-
denaturing, 6% Tris-borate-EDTA acrylamide gels. Signal was assayed using
phosphoimager screens, and the bands were quantified using Amersham’s
ImageQuant software.
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